Roderick Hubbard, Vernalis to Give Presentation at GTCbio’s Kinase Inhibitors Conference

Berlin, Germany, March 17, 2016 --(PR.com)-- Roderick Hubbard, Professor at University of York and Senior Fellow at Vernalis, will give a presentation on “Strategies and Outcomes for Fragments for Kinases” at GTCbio’s 2nd Kinase Inhibitors Design & Screening Conference on May 12-13, 2016 in Berlin, Germany.

Shown below are some key points in Dr. Hubbard’s presentation:

- Fragments and selectivity
- Using crystallographic surrogates for challenging kinases
- Rapid generation of tool compounds to test kinase biology
- Integrating fragments with HTS
- Vernalis’ expertise on DYRK1, PAK1, Pim1, Chk1 and LRRK2

Rod Hubbard has been working with methods for analysis and exploitation of protein structure for nearly 35 years. In the 1980s, he developed molecular graphics and modeling methods. In the 1990s he helped build the Structural Biology Lab at the University of York and determined the structure of many proteins of therapeutic importance; this was combined with studies of protein-ligand interactions and some of the first work in finding small fragments that bind to protein targets. In 1997, he was a founding SAB member of the structure-based pharmaceutical company that became Vernalis. Since 2001, he has spent varying amounts of his time at Vernalis, establishing and applying structure and fragment-based methods for drug discovery. He currently splits his time between York and Vernalis; in addition, he is a member of various boards and panels for the UK Research Councils and consults with pharmaceutical and technology companies around the world.

The 2nd Kinase Inhibitors Design & Screening Conference brings together a mix of academic and industry authoritative experts from leading affiliations (Novartis, Barts Cancer Institute, Genentech, Sanofi-Aventis, Schrodinger, Netherlands Translational Research Center, etc.) to cover many current and relevant aspects of allosteric kinase inhibitors, covalent inhibitor strategies, irreversible and RAF inhibitors, mechanisms of kinase inhibitor resistance, and mutation-focused approaches towards kinase inhibition.

This conference is also part of their larger European Pharma Summit, which consists of three additional conferences:

3rd 3D Models & Drug Screening
3rd GPCR Targeted Screening
10th Drug Design & Medicinal Chemistry

For more information, please visit the website: http://www.gtcbio.com/kinaseinhibitors

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433